cgix presentation 20150902

THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE

September 2015

Investor Presentation NASDAQ: CGIX

INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 2

This presentation contains forward-looking statements within the meaning of the Private Securities LitigationReform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research,technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, alongwith other statements about the future expectations, beliefs, goals, plans, or prospects expressed by managementconstitute forward-looking statements. Any statements that are not historical fact (including, but not limited to,statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also beconsidered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including,without limitation, risks inherent in the development and/or commercialization of potential products, risks ofcancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions willnot be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain futurecapital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended June 30, 2015 along with other filings withthe Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

FORWARD-LOOKING STATEMENT


CANCER GENETICS, INC. INVESTOR HIGHLIGHTSUniquely Positioned to Address Global Market Opportunities in Oncology

3 ACQUISITIONS

$458B GLOBAL ONCOLOGY SPENT BY 2030

Unique &Proprietary Portfolioof GenomicTests & Panels

8 PATENTS

9 TESTS LAUNCHED

Strong & GrowingRelationships withLeading Biotech &Pharma Partners

+650%BIOPHARMACONTRACTS2012-2015

18 RESEARCHCOLLABORATIONS

Innovation &Expertise Drivenby KeyCollaborations

100+ CUMULATIVE YEARSOF EXPERIENCE

World-ClassManagementTeam & ScientificAdvisory Board

55% AAGR

Diversified &High GrowthRevenueStreams


OUR MISSION IS TO BE THE ONCOLOGY DIAGNOSTICS PARTNER OF CHOICE FROM

PARTNERING WITH LEADING RESEARCH INSTITUTIONS TO DEVELOP NEW INSIGHTS & INNOVATIONS

PROVIDING EXPERTISE & EXECUTION TO BIOPHARMA COMPANIES FOR IMPROVED OUTCOMES

RESEARCHCLINICALTRIALS

PATIENTCARE

DELIVERING CRITICALGENOMIC INSIGHTS FOR MEDICAL PROFESSIONALS TO PERSONALIZE PATIENT TREATMENTS


UNIQUELY POSITIONED TO ADDRESS THE MACRO-TRENDSIN TODAY’S ONCOLOGY MARKET ENVIRONMENT

Increasing global need for improved oncologydiagnosis & management1

Committed to a global footprint focused on innovation and state-of-the-art infrastructure and people

Growing awareness and adoption ofgenomic testing by both clinicians and patients2 Highly developed and trained sales

force of 20+ that is uniformly focused on educating and serving clinicians

Majority of cancer clinical trials nowincorporate biomarkers and genomic tests3 Fastest growing area of our business is

focused on incorporating biomarkers into trials for game-changing oncology drugs

Test costs continue to decrease withnewer technologies and improved analytics4

Our focus is the disease and on patient outcomes and are platform agnostic –which makes us uniquely flexible

Industry consolidation seeks to leverageeconomies of scale and expand marketing reach5

Consolidation in our industry is critical to achieving scale, creating a durable business and impacting more patients


OUR MARKET OPPORTUNITY IS GLOBAL & GROWING

CLINICAL$6B$2.5B BIOPHARMA

UNITED STATES

$1B CLINICAL

$0.4B BIOPHARMA

INDIA

$1B BIOPHARMA

CHINA

NEW CANCER PATIENTS DIAGNOSED

GLOBALLY

14.1MIN THE USA:

1.6M50% CAN BE

IMPACTED BYCGI’S PORTFOLIO

IN INDIA:

1M47% CAN BE

IMPACTED BYCGI’S PORTFOLIO

PROJECTED COST OFCANCER CARE BY 2030

$458BAVERAGE COST OF THERAPY

PER CANCER PATIENT

$135K

2015 COST OF CANCER CARE

R&D EXPENDITURE IN BIOPHARMA

GLOBALLY

$115BSPENT IN THE USA

$49BSPENT GLOBALLY

IN ONCOLOGY

$26B

Data from CGI 2014 Annual Report: http://content.stockpr.com/cancergenetics/media/eb1e21488c08d043081d6607733a26f0.pdf

http://www.cancergenetics.com/about-cgi/scientific-advisor/


OUR MARKET SEGMENTS & STRATEGY

COMMERCIALIZATION STRATEGYTARGET MARKET SEGMENTS MARKET OPPORTUNITY

Community HospitalsRegional Cancer CentersOncologists & Pathologists

Continue growing sales force that calls on hospitals & regional labs

Partner with key regional cancer centers and hospitals Focus on both education and collaboration to

differentiate against the “cookie-cutter” labs

Pharmaceutical & Biotechnology Companies

Leverage clinical infrastructure and proprietary product portfolio for testing services that support clinical trials

Expanding the ales emphasis of disease-focused program

Universities &Research Centers

Collaborate to create/validate unique genomic panels and proprietary tests

Accelerate launch of large scale studies to support test adaption & validation (data)

Oncospire Genomics Joint Venture with Mayo Clinic

Emerging MarketsIndia | China

Partner with leading local cancer care providers and hospitals to provide Focus::Hotspot™ and FHACT® in India

Invest in unique sales team and infrastructure to serve markets where nearly a 1/3 of new cancer cases are developing

Partner with select Biopharma clients that need market access

4K+ U.S. HOSPITALS

28K+ ONCOLOGISTS & PATHOLOGISTS

3K+ U.S. CLINICALTRIALS FOR ALLCANCER TYPES

200+ RESEARCHCENTERSIN THE U.S.

1M+ INDIA - CANCER CASES/YEAR

3.1M+ CHINA - CANCERCASES/YEAR

~30% OF TOTAL ANNUALGLOBAL CANCER CASES


ACQUISITIONS

Response Genetics, Inc. (Pending 2015) Leading solid tumor testing franchise with critical clinical

content in Lung, Colorectal, Skin, and Brain cancers Strong commercial presence in Western & Southeast

U.S. with over 3,000 customers Only FDA approved and Medicare reimbursed test for

tumors of unknown origin – TOO™

Bioserve, India (August 2014) First company to provide DNA synthesis, DNA

sequencing, & related services in India Customers and clients include CCMB, ICMR, CSIR

institute, and several major biopharma companies ISO 9001:2015 (185417-205-AQ-IND-RvA)

Gentris, Inc. (July 2014) Global provider of pharmacogenomics, NGS, genotyping,

and biorepository services to Biopharma U.S. FDA-compliant laboratory in Zhanjiang Hi-Tech

Park, Shanghai, China

KEY M&A CRITERIA

Capabilities

Geographic Footprint

Customers & Clients

Unique Content in Cancer

Culture & Human Capital

GLOBAL FOOTPRINTUNITED STATES

RESPONSEGENETICS

NCNJ

INDIA

CHINA

ACTIVE ACQUISITION STRATEGY TO EXPAND GROWTH & ESTABLISH SIGNIFICANT MARKET SHARE GLOBALLY

18,000 sq. ft.

28,000 sq. ft.

14,000 sq. ft.

3,000 sq. ft.

TOTAL 90,000 sq. ft.

27,000 sq. ft.


RESPONSE GENETICS, INC. ACQUISITION HIGHLIGHTS

$8-9MIN CLINICAL & HOSPITAL TESTING

NEW CLINICAL REVENUE

$2-3MEXPECTED FROMNCI’S ALCHEMIST TRIAL & BIOPHARMA CUSTOMERS

ADDITIONAL BIOPHARMA REVENUE & PARTNERS

GEOGRAPHIC REACHSTRONG COMMERCIALPRESENCE IN THEWESTERN & SOUTH EASTERNU.S.A.

SALES FORCE PRESENCEAPPROXIMATELY14 SALES PROFESSIONALS

COMPLEMENTARYONCOLOGY PORTFOLIO

8 of 10solid tumor types

TISSUE OF ORIGIN™: ONLYFDA-CLEARED TEST OF ITS TYPE, MEDICARE APPROVED

EXPERTISE INSOLID TUMORFOCUSED TESTS

$10-12MEXPECTED OVER NEXT 12 MONTHS

ADDITIONAL REVENUECONTRIBUTION


IMPROVING ONCOLOGY CLINICAL TRIAL DEVELOPMENT WITH UNIQUE GENOMIC INSIGHT

CONTRACTS WITH

PHARMACEUTICALCOMPANIES INCLUDING

GILEAD, ASTRA ZENECA, & ROCHE

7 10OF THETOP

70+ CLINICALTRIALS

ACTIVELY PROVIDING TESTING, GENOMIC SERVICES, AND BIOMARKER SUPPORT FOR

$0

$10

$20

$30

+650%INCREASEIN SIGNEDCONTRACTS& POTENTIALREVENUES WITHBIOPHARMACUSTOMERS2012 TO 2015

Approximate expected future revenues under signed contracts with biotechnology & pharma customersfor testing & services to support currently planned clinical trials.

2012 2013 2014 2015 YTD

MIL

LIO

NS VALUE OF

BIOPHARMACONTRACTS

$32

$25

$8$4


ICON PARTNERSHIP & STRATEGIC ALLIANCE

• Partnership w/ ICON offers comprehensive oncology lab testing & solutions for global biopharma• Tests and services offered by CGI through ICON will be branded as “Powered by CGI”• Complementary capabilities for cross and upselling to biotech and pharma customers• CGI capabilities address the needs of ICON’s 900+ oncology studies from Phase I-IV• Cross training of global sales forces & scientific affairs teams scheduled through 2015-16• CGI has already realized quick wins with both joint accounts and joint selling efforts

• CRO industry leader with $1.5B in net annual revenue & 11,000+ employees• Biopharma outsources ~45% of R&D, growing to ~50% by 2016• Top 6 CROs have 55% share, consolidating to ~60% share by 2015• ~30% of ICON revenue is from oncology, in line with industry R&D spend• >33% of drugs in clinical development use biomarkers in trials

UNLOCKING SIGNIFICANT BUSINESS SYNERGIES & ACCELERATING BIOPHARMA REVENUE


OUR EXTENSIVE ONCOLOGY PORTFOLIO IS CENTERED ONFOUR MAJOR PRINCIPLES

III. INNOVATIVE

Focus on UnMet and Critical Disease States Chronic Lymphocytic

Leukemia Renal Cancer Lymphoid

Malignancies Cervical Cancer Lung Cancer Pharmacogenomics Germline & Somatic

I. COMPLETE

Comprehensive & Agnostic

Methodologies Next Generation

Sequencing (NGS) Array-CGH PCR/Sequencing FISH IHC Flow Cytometry

II. COLLABORATIVE

Developed with Though Leaders

Multiple Myeloma & Lung Cancer

OncoSpire Genomics >Mayo Clinic

Cervical CancerFHACT® >National Cancer Institute

Myeloid CancersFocus::Myeloid™ >Columbia University

IV. ACTIONABLE

Impacting Patient Care Community Hospitals Cancer Centers Oncologists Pathologists

Improving Clinical Trials

Pharmaceutical and Biotech companies


UNIQUE, PROPRIETARY PORTFOLIO OF GENOMIC TESTS & PANELS

* Oncospire Genomics: a joint venture with Mayo Clinic

RESEARCH &DISCOVERY

CLINICALDEVELOPMENT

COMMERCIALDEVELOPMENT

MARKETENTRY

FOCUS::MYELOID™ (IN COLLABORATION WITH ILLUMINA)

FOCUS::LYMPHOID™

FOCUS::CLL™ (CLL/SLL)

MATBA® FOR B-CELL CANCERS (CLL, DLBCL, FL, MCL)

TEST IN MARKET

TEST IN MARKET

4 TESTS IN MARKETBLOODCANCERS

Late 2015

MULTIPLE MYELOMA

FOLLICULAR LYMPHOMA

LUNG CANCER

ONCOSPIREGENOMICS*

TBD

Late 2015

Late 2015

TISSUE OF ORIGIN™ (RESPONSE GENETICS) TEST IN MARKET

FOCUS::RENAL™

UROGENRA®-KIDNEY TEST IN MARKET

FHACT® CERVICAL TEST IN MARKET

FOCUS::CANCER HOTSPOT™ (RESEARCH INDIA, BIOPHARMA US) TEST IN MARKET

SOLIDTUMORS

Early 2016

HEREDITARY Late 2015

HEREDITARY CANCER PANEL

COMPREHENSIVE PHARMACOGENOMICS (PGX) PANEL

TBDFOCUSED ON WOMEN’S HEALTH


MATBA® DRIVES IMPROVED INSIGHT & MANAGEMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS

CGI SOLUTION

38% of cases are favorable falling under "watch & wait" approach

8% of unfavorable cases missed by FISH are detected by MatBA®-CLL/SLL

23%

39%

38%

Favorable

Intermediate

Unfavorable

MatBA®-CLL/SLL is CLIA & NYS licensed to stratify patients into 3 distinct risk groups using 20 biomarkers:

CLINICAL NEED

Standard FISH testing for CLL is based on 4 biomarkers & stratifies patients into 2 risk groups:

Favorable/ Intermediate(no distinction)

Unfavorable

FISHTesting

85%

15%


UROGENRA®-KIDNEY GUIDES MANAGEMENT& APPROPRIATE TREATMENT SELECTION

• Patients with renal masses often undergo unnecessary nephrectomy for accurate diagnosis & experience delay in treatment

• Over 15% of needle biopsies of renal masses are rendered non-diagnostic

CLINICAL NEED

• UroGenRA®-Kidney assesses 16 biomarkers in a single assay

• Provides accurate diagnosis guiding appropriate clinical management and treatment strategies (benign vs malignant; malignant subtype)

• Reduction in number of highly invasive procedures & time to treatment initiation

CGI SOLUTION

PROPRIETARY DIAGNOSTIC ALGORITHM

>600 RCC MALIGNANTSUBTYPESin-silico: SNP

>100 MALIGNANT & BENIGNRENAL NEOPLASMSin-house: aCGH & FISH

RETROSPECTIVE IN-HOUSE FFPEVALIDATION (n>190)

100% DIAGNOSTICYIELD 97% DIAGNOSTIC

SENSITIVITYto distinguishbenign/malignant

93% SENSITIVITYto distinguishmalignant RCCsubtypes

PROSPECTIVE ONGOING PERCUTANEOUSCORE NEEDLE BIOPSY (n>190)

DEMONSTRATED ABILITY TO DIAGNOSE PATHOLOGICALLY “UNCLASSIFIABLE” BIOPSIES PRIOR TO SURGICAL INTERVENTION


FHACT® FITS DIRECTLY INTO TODAY’S CERVICAL CANCER SCREENING WORKFLOW

55MPAP SMEARS

3.5MUNCLEAR/

ABNORMAL

2MBIOPSIES

13KCASES OFCANCER

• Today, all HPV+ women with abnormal Pap results are referred for colposcopy

• Several cervical cancer tests are available but the need for less invasive and better informed treatment exists

CLINCAL NEED

• FHACT® helps triage before colposcopy

• Non-invasive test performed on remnant liquid cytology – no resampling is necessary which means no additional doctor visit

• Fewer women referred for colposcopy reducing healthcare costs & patient anxiety

CGI SOLUTION

Today, all these women arereferred for colposcopy

PROGRESS to a higher grade andincreased risk for cancer within10-30 years of the infection

REGRESS within 2 years ofthe infection

Not referred for colposcopy

FHACT®

Results:Normal

Referred for colposcopy

FHACT®

Results:Abnormal

~90% ~10%

HPV+ women with abnormal or unclear liquid-based cytology


ARCHITECTURE OF THE FOCUS::LYMPHOMA™ NGS PANEL

ABCB1 ABCC1 ABCG2 CYP1A1 CYP1A2 UGT1A6

CYP2A6 CYP2B6 CYP2C19 CYP2C8 CYP2C9 ABCB4

CYP2D6 CYP2E1 CYP3A4 CYP3A5 DPYD HNMT

GSTM1 GSTP1 NAT1 NAT2 SLC15A2 SLC28A3

SLC22A1 SLC22A2 SLC22A6 SLCO1B1 SLCO2B1 FMO2

SLCO1B3 TPMT UGT1A1 UGT2B15 UGT2B17 SLC10A2

UGT2B7 ABCC2 GSTT1 VKORC1 HLA-A CYP1B1

HLA-B G6PD UGT1A9 MTHFR F5 HNRNPD

SLCO1A2 COMT TYMS ERCC1 ERCC2 IKBKE

XRCC1 ABCC5 SLC19A1 SULT1A1 NCF4 ERBB2

SEC14L3 CYBA RAC2 POR SULT2B1 SLC28A1

FMO3 SPG7 ADH7 EPO LARP1B RRM1

ACTG1 SOX10 NR1I3 BCL2 AGXT CAPG

OPRM1 LRP2 NME1 SCN10A

























































ABCA13 BIRC3 CDKN2B EPHA7 HIST1H1C JAK2 NFKBIB PIK3CG RAF1 SYK

ABCA3 BLK CIITA ERBB3 HIST1H1E KDM6B NLGN2 PIK3R1 RAPGEF1 SYNJ2

ABCC4 BLNK CNOT6L ETS1 HIST1H2BC KDR NLK PIK3R2 RB1 TBL1XR1

ABCC9 BRAF COL16A1 EZH2 HIST1H3B KIT NOTCH1 PIKFYVE RGS4 TCF4

ABL1 BRD4 CREBBP FAS HIST1H4I KLHL6 NOTCH2 PIM1 RHOA TEC

ACTB BTG1 CSMD3 FAT2 HIST2H2BE KRAS NOX4 PLCB1 ROBO2 TET2

ACTN1 BTG2 CSNK1D FAT4 HRAS LRP1 NR3C1 PLCB4 ROCK2 TLR2

ADAM10 BTK CTBP2 FBXO11 ID3 LRP6 NRAS PLCD1 ROS1 TMEM30A

AHR CARD10 CTNNA2 FGFR1 IGSF1 LRRC7 NTRK1 PLCD3 RRAGC TNF

AKT CARD11 DCC FLT1 IKBKB LYST TENM4 PLCE1 S1PR2 TNFAIP3

APC CARM1 DCP1B FOXO1 IKZF1 MALT1 OGDHL PLCG2 SALL3 TNFRSF11A

APC2 CCND1 DDX21 FOXP1 IKZF3 MAP2K1 P2RX5 PLCZ1 SEMA6C TNFRSF14

AQR CCND3 DGKZ FYN INPP5B MED12 P2RY8 POT1 SF3B1 TNIK

ARID1A CD22 DHDH GCC2 IRF4 MEF2B PARP1 POU2AF1 SGK1 TNRC6B

ATM CD36 DLC1 GNA13 IRF8 MLL2 PDCD1 POU2F2 SI TP53

ATP11C CD58 DSEL GNAI2 ITGB3 MLL3 PDGFRA PRDM1 SLC17A6 TRAF2

ATP6AP1 CD70 DTX1 GPR112 ITPK1 MLLT6 PDK1 PRKCA SLC30A4 TRIM8

B2M CD79A DUSP2 GRB2 ITPKB MRGPRF PIK3AP1 PRKCB SMARCA4 UBR5

BAP1 CD79B DUSP27 GRIN2A ITPR1 MTOR PIK3C2A PRKDC SOCS1 VAV1

BCL10 CDIPT EBF1 GSK3B ITPR1 MYC PIK3C2G PTEN SP140 WHSC1

BCL2 CDK4 EIF2AK4 HCK ITPR2 MYD88 PIK3C3 PTPN13 STAT3 XPO1

BCL6 CDKN2A EP300 HIST1H1B JAK1 NFKBIA PIK3CD PYHIN1 STAT6 ZMYM3

Outcome/Cell of OriginClinical TargetsAssociated with

BCR/PI3K/WNT pathwayLocated within aberration

(DLBCL only)

In total, 220 genes were selected based on frequency of mutation, theranostic, diagnostic, and prognostic associations as well as their potential to interact with known dysregulated pathways in B-cell lymphoma


FOCUS::LYMPHOMA™ – TARGETED, DISEASE-FOCUSED PANEL

DLBCL

MCLFL

31 MARKERS

25 MARKERS 11 MARKERS

89 1825

1

FOCUS::LYMPHOMA™

220 genes of interest for lymphomasLYMPHOMA PANEL COMPARISONFocus::Lymphoma™ vs. FoundationOne Heme

110110 MARKERS 296 MARKERS

Focus::Lymphoma™

PanelFoundationOne

Heme Panel

• Only 110 of the 220 Focus::Lymphoma™ panel genes are included in the FoundationOne Heme panel

• Many important sets of genes are missing from FoundationOne Heme including:

• BCR Signaling genes (x4)• PI3K Pathway genes (7)


ONCOSPIRE GENOMICS JOINT VENTURE BETWEEN CANCER GENETICS & MAYO CLINIC

• Joint venture based in Rochester, MN

• Goal: to develop tests that will become the gold standard in diagnosing and managing patients with selected disease targets

• Diseases with known clinical dilemmas were selected and informed by clinicians in the Mayo Clinic network

• OncoSpire has the rights to druggable targets that are discovered

SELECTED PROJECTS PIPELINE:

200,000 NEW CASESPER YEAR MULTIPLE MYELOMA

LUNG CANCER

FOLLICULAR LYMPHOMA

1.6M NEW CASESPER YEAR

RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY

Q4 2015 Expected Launch

20,920 NEW CASESPER YEAR


Disease Target Collaboration Highlights

Beth Israel Deaconess Medical Ctr DLBCL Biomarker-based outcome prediction

Cleveland Clinic Kidney Cancer Genomic marker validation

Columbia University AML, MDS, and Myeloid Cancers NGS panel development

Dana-Farber Cancer Institute CLL CLL outcome scheme validation

Georgia Regents University DLBCL Diagnosis, prognosis & management

Hackensack University Medical Ctr CLL Further validation of MatBA®-CLL regions

Kamineni Hospital, India Cervical Cancer FHACT® evaluation

Keck Medicine of USC DLBCL Genomic panel evaluation & optimization

Memorial Sloan-Kettering Cancer Ctr CLL, DLBCL, FL, MCL, Kidney Multiple collaborations

Moffitt Cancer Center CINV and PGx Prediction of Side Effects Associated With Chemo

National Cancer Institute Cervical Cancer FHACT® development

North Shore LIJ Health System CLL/SLL CLL/SLL validation & BTK inhibitor resistance

Stanford University DLBCL Risk stratification

University of Alabama Central Nervous System Lymphoma Biomarker investigation

University of Iowa Cancer Center Cervical Cancer, DLBCL FHACT® evaluation & MatBA®-DLBCL validation

Westchester Medical Center Central Nervous System Lymphoma Genomic biomarker identification using UroGenRA®

COLLABORATIONS WITH PREMIER CANCER RESEARCH INSTITUTIONS


CGI’S DISEASE-FOCUSED PATENT PORTFOLIO

Gynecological Cancers & Precancers

Chromosomal Analysis Using FISH

Gene Expression

Renal Cortical Neoplasms

Tissue of Origin

Mature B-Cell Neoplasms

HPV-Associated Cancers

2 US Patents | EU | India | CanadaMature B-Cell Neoplasms

3 US PatentsTissue of Origin*

2 US Patents | EURenal Cortical Neoplasms

13 US Patents | PCT | AU | CA | China | JapanGene Expression*

2 US Patents | CanadaChromosomal Analysis Using FISH

2 US Applications Filed | PCTGynecological Cancers & Precancers

2 US Patents | PCTHPV-Associated Cancers

* Acquired from Response Genetics. Transaction Pending

Through 2031

Through 2030

Through 2029

Through 2027

Through 2023

Through 2022

2 Patents

2 Patents

3 Patents

2 Patents

13 Patents

2 Patents

2 Filed


DIVERSIFIED AND GROWING REVENUE BASE

55% 43%

2%

Full Year2014

$10.2M

70% 25%

5%

1H2015

$8.6M

CGI’s business is not over-dependent on third partyreimbursement. In 1H 2015, Medicare represented 6%and other insurers represented 6% of consolidatedrevenue.

• Entered into partnership with ICON to offer access to ICON Laboratory Services combined with Cancer Genetics' Focus::CLL™ chosen for global clinical trial by leading biotechnology company

BIOPHARMA GLOBAL BIOTECH ANDPHARMACEUTICAL COMPANIES

• Launched new NGS panels, including Focus::Myeloid™ • Entered into preliminary agreement to acquire

Response Genetics (OTCQB:RGDX)

CLINICAL CANCER CENTERS, HOSPITALS, REGIONAL LABS, AND CLINICIANS

• New research studies with leading cancer centers and academic institutions

• Selected by regenerative medicine company, ReproCELL, Inc., to provide (NGS) services

DISCOVERY PRECLINICAL RESEARCH GROUPS AT ACADEMIC,GOVERNMENT & COMMERCIAL ORGANIZATIONS


STRONG RECORD OF CONTINUOUS GROWTH

2011

2012

2013

2014

0

5

10$10.2

$6.6

$4.3

$3.0

$10M

$5M112%BIOPHARMA REVENUE GROWTH FROM 2013 to 2014

TOTAL REVENUE GREW FROM

$6.6M TO $10.2M

54% REVENUE GROWTHFROM 2013 TO 2014

2013 2014

$0M

REVENUE GROWTH BY YEAR


1H 2012

1H 2013

1H 2014

1H 2015

0

$8.6

$2.9$3.1

$2.0

STRONG RECORD OF CONTINUOUS GROWTH

567%BIOPHARMA REVENUE GROWTH FROM 1H 2014

1H TOTAL REVENUE GREW FROM

$2.9M TO $8.6M

191% REVENUE GROWTHFROM 1H 2014

2014 2015

$8M

$4M

$0M

FIRST HALF (1H) 2015 REVENUE GROWTH


PROFORMA REVENUE WITH PROPOSED ACQUISITION

$5.2M ~$38M

ADDITIONAL REVENUE BACKLOG FROMBIOPHARMA TRIALS

1H TOTAL REVENUE WOULD INCREASE$8.6M TO $16.3M

$34M to $40MANNUAL REVENUE RUN RATE

1H 2015 1H 2015 (Proforma)

2013 THRU FIRST HALF (1H) 2015 REVENUE

CGIX RESPONSE

0

5

10

15

20

25

30

FY13 FY14 1H -2015

$26.4MTotal

$26.9MTotal

$16.3M1st Half

$19.8M $16.7M

$7.7M

$6.6M$10.2M $8.6M


STANDALONE SUMMARY STATEMENT OF OPERATIONS SUMMARIZED INCOME STATEMENTS (dollars in thousands)

SUMMARIZED BALANCE SHEET (dollars in thousands)

1H, 2014 1H, 2015REVENUE $2,942 8,555Gross Profit 149 2,316Gross Margin (%) 5% 27%Research & Development 1,703 2,533Sales & Marketing 1,667 2,300General & Administrative 5,127 6,049OPERATING PROFIT (Loss) ($8,348) ($8,566)NET INCOME (Loss) ($6,673) ($9,258)NON CASH ADJUSTMENTS $1,637 $2,812NET INCOME (Loss) EXCLUDING NON CASH ITEMS + ($5,036) ($6,446)

Actual 06/30/15

ALL CASH* $23,744

STOCKHOLDERS’ EQUITY $26,772* All cash includes $6,300 of restricted cash. * $6,000 of that is now unrestricted as of May 7, 2015.* (Cancer Genetics, Inc. 2014 YE 10Q, page 77)

+ This is non GAAP+ measure – see slide 29+ for computation


HISTORICAL CLINICAL REIMBURSEMENT MIX & PAYER COVERAGE

COVERED LIVES REPRESENTED BY RECENT AGREEMENTS WITH NATIONAL INTEGRATED NETWORKS• America’s Choice Provider• Blue Cross Blue Shield of California• Blue Cross Blue Shield of Illinois• Blue Cross Blue Shield of North Carolina• Credentialing Organizations (NCQA, CAQH)• Encore Health Network• Harvard Pilgrim Health Plan • Market-specific Medicaid plans (IL, CA, TX, FL, NY, NJ)• Medicare Railroad• MultiPlan• TRICARE military plan

36%

29%

REGIONALAND NATIONAL

PAYERS

MEDICARE

COMMERCIALPAYERS

CGI PAYMENT HISTORY(CLINICAL REVENUES ONLY)

35%

DIRECT BILL

MORE THAN

50M


EXPERIENCED LEADERSHIP TEAM

Mandar Kulkarni, PhDChief Technology Officer, India

Randy Goodman, PhDDirector, Reimbursement & Clinical Revenue Cycle Management 20+ years of health economics, reimbursement, payer relations experience Healthcare Mgmt Solutions, Scientia Advisors, ImpediMed White House Healthcare Reform Policy Consultant to Presidents Clinton & Obama

Scott Clark, PhDVP, Global QA & Biopharma Development 16+ years at pharma and clinical research companies CAP Biorepository Director and oversees China operations Gentris Corporation founding management team

Rob Fannon, MBA, MPHVP, Biopharma Operations 10+ years operations, client mgmt, and molecular test & panel dev. 5 years in life science and pharmaceutical equity research Roche Molecular Diagnostics, BioServe Biotechnologies, Ltd.

Steve HepburnEVP, Market Development, Biopharma Services 30+ years in the molecular diagnostics & clinical research arena PPD, Omnicare Clinical Research, VivoMetrics, Quintiles Launched Multiplexed ICE COLD-PCR(liquid biopsy platform)

Panna SharmaChief Executive Officer & President, Board Member 15+ years as advisor to global life science & healthcare companies TSG Partners, iXL Enterprises, Interactive Solutions, Putnam Investment

Edward J. Sitar, CPAChief Financial Officer & Treasurer

Rita Shaknovich, MD, PhDGroup Medical Director & VP, Hematopathology Services

Jane Houldsworth, PhDVP, Research & Development 25+ years in translational oncology research MSKCC, CALTECH Principal investigator of multiple Phases & Independent Investigator Award

Greg AshVP, Clinical Market Development 16+ years in the healthcare sector Go Path Laboratories, Response Genetics, Eisai Oncology Launched Halavan (treating metastatic breast cancer) & Marketing for Dacogen (MDS)

30+ years in finance & deal making in the healthcare industry ActiveHealth Management (Aetna), Cadent, MIM Corp, Coopers & Lybrand (PWC) 10 transactions raising $150+ million, 12+ acquisition transactions

5+ years in both clinical (M/Z Dx) and genomic (Sandor LS) development NIH grantee and two Young investigator awards Scientific collaborations, business development, strategic alliances

15+ years in both clinical and research capacities Weill Cornell Medial College, Mount Sinai Hospital, Columbia Presbyterian Hospital,

Albert Einstein Hospital Head of Laboratory at Weill Cornell Medical College Heme Onc. Division


COMPANY FACTS & BOARD OF DIRECTORS

SCIENTIFIC ADVISORYBOARD

Andrea Califano, PhDTimothy Chan, MD, PhDAhmet Dogan, MD, PhDRiccardo Dalla-Favera, MDHoward McLeod, PharmDVundavalli Murty, PhDHans-Guido Wendel, MD

Panna Sharma Michael J. Welsh, MD c, g• Investigator at the Howard Hughes Medical Inst.• Roy J. Carver Biomed Research Chair in Internal

Medicine & Molecular Physiology & Biophysics• Director of Univ. of Iowa Inst. for Biomed Discovery

• CEO & president of Cancer Genetics• General Manager of OncoSpire Genomics• Previously managing partner/founder of TSG Partners• 70+ buy & sell-side transactions (healthcare companies)

Howard McLeod, PharmD g Franklyn Prendergast, MD, PhD a, c, g• Director of Mayo Clinic for Individualized Medicine• Currently on boards of: Translational Genomics

Research Inst.; Infectious Disease Research Inst.;DemeRx, Inc.; Ativa; Eli Lilly & Co.

• Personalized Medicine Medical Director at Moffitt• Founding Director of the Univ. of NC Institute for

Pharmacogenomics (PGx) & Individualized Therapy• 475+ peer-reviewed papers (PGx, applied therapeutics)

Raju S.K. Chaganti, PhD Geoffrey Harris, CFA a• 30+ years experience as healthcare analyst &

portfolio manager for biotech/life sci companies• Portfolio manager/managing partner at c7 Advisors• Previously: Cantor Fitzgerald; Gleacher & Company

• Founded CGI & served as Chairman until 2014• Internat’ly recognized leader in molecular genetics• Co-discovered lymphoma & kidney cancer patents• Incumbent of the William Snee E. Chair at MSKCC

John Pappajohn Non-Executive Chairman Ted Cannon a, c• Founder & President of Clinical Research Center

of Cape Cod• Previously at Franey Medical Labs; Pharmacia

Diagnostics; Alletess

• Involved in 100+ start-up companies• Served as director of 40+ public companies• Currently on boards of: American CareSource

Holdings; ConMed Healthcare Mgmt; CNS Response

For complete bios, see web link below:cancergenetics.com/about-cgi/scientific-advisor/

NASDAQ: CGIX

MARKET CAP: 110.55 M

AUDITORS: McGladrey LLP

LEGAL: Lowenstein Sandler LLP

a: Audit Committee c: Compensation Committee g: Governance and Nominating Committee

http://www.cancergenetics.com/about-cgi/scientific-advisor/


CONSISTENT ACHIEVEMENT OF MILESTONES EXPECTED IN COMING QUARTERS

REIMBURSEMENT & MARKET ADOPTION• Increasing covered lives market access through add’l payers & health care organizations• Additional international agreements for FHACT® distribution and co-marketing

partnerships in key geographies

NEXT GENERATION SEQUENCING PANELS• Launching multi-marker NGS panel for lymphoid malignancies• Multiple Myeloma NGS panel launch, Oncospire Second half of 2015

DATA TO SUPPORT PRODUCTS• Lymphoid, Myeloid and CLL Panels - Additional data and results to support clinical usage, patient value and payor coverage• FHACT® - Additional data from a study conducted in conjunction with NCI and more published papers focused on FHACT®,

including a health economic study

BIOPHARMA REVENUES & MARKET SHARE• Additional news on biopharma partners & relationships• Major collaborations with US & Asia biopharma companies

LATE PHASES OF FINALIZING SIGNIFICANT PARTNERSHIPS TO EXPAND BIOPHARMA BUSINESS


CANCER GENETICS, INC. INVESTOR HIGHLIGHTS

Uniquely Positioned to Address Global Market Opportunities in Oncology

3 ACQUISITIONS

$458B GLOBAL ONCOLOGY SPENT BY 2030

Unique &Proprietary Portfolioof GenomicTests & Panels

8 PATENTS

9 TESTS LAUNCHED

Strong & GrowingRelationships withLeading Biotech &Pharma Partners

+650%BIOPHARMACONTRACTS2012-2015

18 RESEARCHCOLLABORATIONS

Innovation &Expertise Drivenby KeyCollaborations

100+ CUMULATIVE YEARSOF EXPERIENCE

World-ClassManagementTeam & ScientificAdvisory Board

55% AAGR

Diversified &High GrowthRevenueStreams

THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE

CGI Headquarters201 Route 17 North, 2nd Fl.Rutherford, NJ 07070

Phone: +1 201-528-9200Fax: +1 201-528-9235

RUTHERFORD, NJResearch Triangle Park133 Southcenter Court, S.400Morrisville, NC 27569

Phone: +1 919-465-0100Fax: +1 919-465-0554

RALEIGH, NC#3-1-135 / 1A CNR ComplexMallapur Main Road, R.R. Dst.Hyderabad – 500 076, Telangana

Toll-free: +91 040-2717-8178Fax: +91 040-2717-8176

HYDERABAD, INDIA781 Cai Lun Road, Room 803Shanghai 201203P.R. China

Toll-free: +91 040-2717-8178Fax: +91 040-2717-8176

SHANGHAI, CHINA

WWW.CGIX.COM

WWW.CANCERGENETICS.COM

cgix presentation 20150902

Health & Medicine